Panobinostat

Pricing Availability   Qty
Description: Pan-histone deacetylase inhibitor
Chemical Name: (2E)-N-Hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide
Purity: ≥98% (HPLC)
Datasheet
Citations
Reviews
Literature (2)

Biological Activity for Panobinostat

Panobinostat is a potent pan-histone deacetylase (HDAC) inhibitor (IC50 values = 2.1 - 531 nM). Panobinostat induces histone H3 and H4 acetylation and potently inhibits cell proliferation and cell viability in HH, BT474 and HCT116 cells (IC50 are 1.8, 2.6 and 7.1 nM, respectively) in vitro. It leads to significant tumor regression of up to 94% in an HH CTCL mouse xenograft model. Panobinostat inhibits the DNA binding activity of STAT5 in leukemia cell lines and acts synergistically with 17-AAG (Cat. No. 1515) to induce apoptosis. The compound shows potent antimyeloma activity, including in drug-resistant cell lines. Panobinostat also induces a significant increase in cell-associated unspliced (CA-US) HIV-1 RNA from CD4+ T cells and leads to activation of transcription of proviruses. Panobinostat simultaneously suppresses the expression of angiotensin-converting enzyme 2 (ACE2) and ABO in epithelial cell lines. Antimalarial and orally bioavailable.

Technical Data for Panobinostat

M. Wt 349.43
Formula C21H23N3O2
Storage Store at -20°C
Purity ≥98% (HPLC)
CAS Number 404950-80-7
PubChem ID 6918837
InChI Key FPOHNWQLNRZRFC-ZHACJKMWSA-N
Smiles ONC(/C=C/C(C=C1)=CC=C1CNCCC2=C(C)NC3=CC=CC=C23)=O

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data for Panobinostat

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 34.94 100

Preparing Stock Solutions for Panobinostat

The following data is based on the product molecular weight 349.43. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 2.86 mL 14.31 mL 28.62 mL
5 mM 0.57 mL 2.86 mL 5.72 mL
10 mM 0.29 mL 1.43 mL 2.86 mL
50 mM 0.06 mL 0.29 mL 0.57 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

References for Panobinostat

References are publications that support the biological activity of the product.

Atadja (2009) Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. Cancer Lett. 280 233 PMID: 19344997

Maiso et al (2006) The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Res. 66 5781 PMID: 16740717

George et al (2005) Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood 105 1768 PMID: 15514006

Barton et al (2016) Broad activation of latent HIV-1 in vivo. Nat.Commun. 7 12731 PMID: 27605062

Takahashi et al (2021) Histone deacetylase inhibitors suppress ACE2 and ABO simultaneously, suggesting a preventive potential against COVID-19. Sci.Rep. 11 3379 PMID: 33564039


If you know of a relevant reference for Panobinostat, please let us know.

View Related Products by Product Action

View all Non-selective Histone Deacetylase Inhibitors

Keywords: Panobinostat, Panobinostat supplier, pan, histone, deacetylase, HDAC, inhibitor, inhibits, tumor, regression, H3, H4, acetylation, antimyeloma, cell-associated, unspliced, CA-US, HIV-1, RNA, angiotensin-converting, enzyme, 2, ACE2, ABO, COVID-19, antimalarial, malaria, Non-selective, HDACs, Antimalarials, 7629, Tocris Bioscience

Citations for Panobinostat

Citations are publications that use Tocris products.

Currently there are no citations for Panobinostat. Do you know of a great paper that uses Panobinostat from Tocris? Please let us know.

Reviews for Panobinostat

There are currently no reviews for this product. Be the first to review Panobinostat and earn rewards!

Have you used Panobinostat?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Epigenetics Scientific Review

Epigenetics Scientific Review

Written by Susanne Müller-Knapp and Peter J. Brown, this review gives an overview of the development of chemical probes for epigenetic targets, as well as the impact of these tool compounds being made available to the scientific community. In addition, their biological effects are also discussed. Epigenetic compounds available from Tocris are listed.

Rheumatoid Arthritis Poster

Rheumatoid Arthritis Poster

Rheumatoid arthritis (RA) is a chronic destructive inflammatory autoimmune disease that results from a breakdown in immune tolerance, for reasons that are as yet unknown. This poster summarizes the pathology of RA and the inflammatory processes involved, as well as describing some of the epigenetic modifications associated with the disease and the potential for targeting these changes in the discovery of new treatments.